PDCD1 and neoplasm: Other factors contributing to immunotherapy resistance include the scarcity of tumor-infiltrating CD8+ T cells, PD-L1 overexpression, loss/overexpression of PD-1, lack of neoantigens, and upregulation of additional immune checkpoint receptors (i.e., CTLA-4, LAG 3) [110,111,112].